Vanguard Capital Management
KALV

Vanguard Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Vanguard Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,830,467
Closed -$36.8M – 4123
2026
Q1 		$36.8M Buy
+1,830,467
New +$29.5M ﹤0.01% 2017

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Capital Management's KALV Position: Q2 2026 in Review

Vanguard Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 1,830,467 shares — an estimated $36.8M sold.

Vanguard Capital Management first reported a position in KALV in Q1 2026 and held it in 1 quarter. The position peaked at $36.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Vanguard Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Capital Management sold 1,830,467 KalVista Pharmaceuticals shares in Q2 2026, an estimated $36.8M.
  • Vanguard Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Capital Management's KalVista Pharmaceuticals position peaked at $36.8M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.